Mitochondrial Fus1/Tusc2 and cellular Ca2
Journal
Cancer gene therapy
ISSN: 1476-5500
Titre abrégé: Cancer Gene Ther
Pays: England
ID NLM: 9432230
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
13
10
2021
accepted:
28
01
2022
revised:
22
12
2021
pubmed:
20
2
2022
medline:
20
10
2022
entrez:
19
2
2022
Statut:
ppublish
Résumé
FUS1/TUSC2 (FUSion1/TUmor Suppressor Candidate 2) is a tumor suppressor gene (TSG) originally described as a member of the TSG cluster from human 3p21.3 chromosomal region frequently deleted in lung cancer. Its role as a TSG in lung, breast, bone, and other cancers was demonstrated by several groups, but molecular mechanisms of its activities are starting to unveil lately. They suggest that Fus1-dependent mechanisms are relevant in etiologies of diseases beyond cancer, such as chronic inflammation, bacterial and viral infections, premature aging, and geriatric diseases. Here, we revisit the discovery of FUS1 gene in the context of tumor initiation and progression, and review 20 years of research into FUS1 functions and its molecular, structural, and biological aspects that have led to its use in clinical trials and gene therapy. We present a data-driven view on how interactions of Fus1 with the mitochondrial Ca
Identifiants
pubmed: 35181743
doi: 10.1038/s41417-022-00434-9
pii: 10.1038/s41417-022-00434-9
pmc: PMC9576590
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Tumor Suppressor Proteins
0
TUSC2 protein, human
0
Types de publication
Journal Article
Review
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1307-1320Subventions
Organisme : NCI NIH HHS
ID : SC1 CA182843
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA163069
Pays : United States
Organisme : NIMHD NIH HHS
ID : U54 MD007593
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Sever R & Brugge JS. Signal transduction in cancer. Cold Spring Harb Perspect Med. 2015;5:a006098.
Sherr CJ. Principles of tumor suppression. Cell 2004;116:235–46.
pubmed: 14744434
doi: 10.1016/S0092-8674(03)01075-4
Okochi-Takada E, Hattori N, Tsukamoto T, Miyamoto K, Ando T, Ito S, et al. ANGPTL4 is a secreted tumor suppressor that inhibits angiogenesis. Oncogene 2014;33:2273–8.
pubmed: 23686315
doi: 10.1038/onc.2013.174
Kontomanolis EN, Koutras A, Syllaios A, Schizas D, Mastoraki A, Garmpis N, et al. Role of oncogenes and tumor-suppressor genes in carcinogenesis: a review. Anticancer Res. 2020;40:6009–15.
pubmed: 33109539
doi: 10.21873/anticanres.14622
Wang LH, Wu CF, Rajasekaran N, Shin YK. Loss of tumor suppressor gene function in human cancer: an overview. Cell Physiol Biochem. 2018;51:2647–93.
pubmed: 30562755
doi: 10.1159/000495956
Hwang GR, Yuen JG & Ju J. Roles of microRNAs in gastrointestinal cancer stem cell resistance and therapeutic development. Int J Mol Sci. 2021;22:1624.
Datta N, Chakraborty S, Basu M, Ghosh MK. Tumor suppressors having oncogenic functions: the double agents. Cells 2020;10:1.
doi: 10.3390/cells10010046
Payne SR, Kemp CJ. Tumor suppressor genetics. Carcinogenesis 2005;26:2031–45.
pubmed: 16150895
doi: 10.1093/carcin/bgi223
Grzywa TM, Klicka K & Wlodarski PK. Regulators at every step-how microRNAs drive tumor cell invasiveness and metastasis. Cancers. 2020;12:3709.
Lerman MI, Minna JD. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. Cancer Res. 2000;60:6116–33.
pubmed: 11085536
Sekido Y, Ahmadian M, Wistuba II, Latif F, Bader S, Wei MH, et al. Cloning of a breast cancer homozygous deletion junction narrows the region of search for a 3p21.3 tumor suppressor gene. Oncogene 1998;16:3151–7.
pubmed: 9671394
doi: 10.1038/sj.onc.1201858
Zabarovsky ER, Lerman MI, Minna JD. Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene 2002;21:6915–35.
pubmed: 12362274
doi: 10.1038/sj.onc.1205835
Lu C, Stewart DJ, Lee JJ, Ji L, Ramesh R, Jayachandran G, et al. Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. PLoS ONE. 2012;7:e34833.
pubmed: 22558101
pmcid: 3338819
doi: 10.1371/journal.pone.0034833
Ji L, Roth JA. Tumor suppressor FUS1 signaling pathway. J Thorac Oncol. 2008;3:327–30.
pubmed: 18379348
pmcid: 3370667
doi: 10.1097/JTO.0b013e31816bce65
Akhbariyoon H, Azizpour Y, Esfahani MF, Firoozabad MSM, Rad MR, Esfahani KS, et al. Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials. Clin Immunol. 2021;232:108873.
pubmed: 34688855
doi: 10.1016/j.clim.2021.108873
Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50:1–11.
pubmed: 30546008
doi: 10.1038/s12276-018-0191-1
Gaynor N, Crown J & Collins DM. Immune checkpoint inhibitors: key trials and an emerging role in breast cancer. Semin Cancer Biol. 2020; S1044-579X(20):30152–8.
Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer. 2018;118:9–16.
pubmed: 29319049
pmcid: 5765236
doi: 10.1038/bjc.2017.434
Schoenfeld AJ, Hellmann MD. Acquired resistance to immune checkpoint inhibitors. Cancer Cell. 2020;37:443–55.
pubmed: 32289269
pmcid: 7182070
doi: 10.1016/j.ccell.2020.03.017
Meraz IM, Majidi M, Cao X, Lin H, Li L, Wang J, et al. TUSC2 immunogene therapy synergizes with anti-PD-1 through enhanced proliferation and infiltration of natural killer cells in syngeneic Kras-mutant mouse lung cancer models. Cancer Immunol Res. 2018;6:163–77.
pubmed: 29339375
pmcid: 5909977
doi: 10.1158/2326-6066.CIR-17-0273
Hood MI, Uzhachenko R, Boyd K, Skaar EP, Ivanova AV. Loss of mitochondrial protein Fus1 augments host resistance to Acinetobacter baumannii infection. Infect Immun. 2013;81:4461–9.
pubmed: 24042119
pmcid: 3837987
doi: 10.1128/IAI.00771-13
Ivanova AV, Ivanov SV, Pascal V, Lumsden JM, Ward JM, Morris N, et al. Autoimmunity, spontaneous tumourigenesis, and IL-15 insufficiency in mice with a targeted disruption of the tumour suppressor gene Fus1. J Pathol. 2007;211:591–601.
pubmed: 17318811
doi: 10.1002/path.2146
Uzhachenko R, Boyd K, Olivares-Villagomez D, Zhu Y, Goodwin JS, Rana T, et al. Mitochondrial protein Fus1/Tusc2 in premature aging and age-related pathologies: critical roles of calcium and energy homeostasis. Aging. 2017;9:627–49.
pubmed: 28351997
pmcid: 5391223
doi: 10.18632/aging.101213
Uzhachenko R, Ivanov SV, Yarbrough WG, Shanker A, Medzhitov R, Ivanova AV. Fus1/Tusc2 is a novel regulator of mitochondrial calcium handling, Ca2+-coupled mitochondrial processes, and Ca2+-dependent NFAT and NF-kappaB pathways in CD4+ T cells. Antioxid Redox Signal. 2014;20:1533–47.
pubmed: 24328503
pmcid: 3942676
doi: 10.1089/ars.2013.5437
Uzhachenko R, Shanker A, Yarbrough WG, Ivanova AV. Mitochondria, calcium, and tumor suppressor Fus1: At the crossroad of cancer, inflammation, and autoimmunity. Oncotarget 2015;6:20754–72.
pubmed: 26246474
pmcid: 4673227
doi: 10.18632/oncotarget.4537
Hansford S, Huntsman DG. Boveri at 100: Theodor Boveri and genetic predisposition to cancer. J Pathol. 2014;234:142–5.
pubmed: 25074498
Whang-Peng J, Bunn PA Jr, Kao-Shan CS, Lee EC, Carney DN, Gazdar A, et al. A nonrandom chromosomal abnormality, del 3p(14-23), in human small cell lung cancer (SCLC). Cancer Genet Cytogenet. 1982;6:119–34.
pubmed: 6286098
doi: 10.1016/0165-4608(82)90077-2
Whang-Peng J, Kao-Shan CS, Lee EC, Bunn PA, Carney DN, Gazdar AF, et al. Specific chromosome defect associated with human small-cell lung cancer; deletion 3p(14-23). Science. 1982;215:181–2.
pubmed: 6274023
doi: 10.1126/science.6274023
de Leij L, Postmus PE, Buys CH, Elema JD, Ramaekers F, Poppema S, et al. Characterization of three new variant type cell lines derived from small cell carcinoma of the lung. Cancer Res. 1985;45:6024–33.
pubmed: 2998591
Kok K, Osinga J, Carritt B, Davis MB, van der Hout AH, van der Veen AY, et al. Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. Nature 1987;330:578–81.
pubmed: 2825033
doi: 10.1038/330578a0
Naylor SL, Johnson BE, Minna JD, Sakaguchi AY. Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. Nature 1987;329:451–4.
pubmed: 2821400
doi: 10.1038/329451a0
Scholes AG, Liloglou T, Maloney P, Hagan S, Nunn J, Hiscott P, et al. Loss of heterozygosity on chromosomes 3, 9, 13, and 17, including the retinoblastoma locus, in uveal melanoma. Invest Ophthalmol Vis Sci 2001;42:2472–7.
pubmed: 11581185
Carroll PR, Murty VV, Reuter V, Jhanwar S, Fair WR, Whitmore WF, et al. Abnormalities at chromosome region 3p12-14 characterize clear cell renal carcinoma. Cancer Genet Cytogenet. 1987;26:253–9.
pubmed: 3471307
doi: 10.1016/0165-4608(87)90059-8
Johansson B, Billstrom R, Kristoffersson U, Akerman M, Garwicz S, Ahlgren T, et al. Deletion of chromosome arm 3p in hematologic malignancies. Leukemia 1997;11:1207–13.
pubmed: 9264371
doi: 10.1038/sj.leu.2400718
Kok K, Naylor SL, Buys CH. Deletions of the short arm of chromosome 3 in solid tumors and the search for suppressor genes. Adv Cancer Res. 1997;71:27–92.
pubmed: 9111863
doi: 10.1016/S0065-230X(08)60096-2
Larson AA, Kern S, Curtiss S, Gordon R, Cavenee WK, Hampton GM. High resolution analysis of chromosome 3p alterations in cervical carcinoma. Cancer Res. 1997;57:4082–90.
pubmed: 9307297
Larson AA, Liao SY, Stanbridge EJ, Cavenee WK, Hampton GM. Genetic alterations accumulate during cervical tumorigenesis and indicate a common origin for multifocal lesions. Cancer Res. 1997;57:4171–6.
pubmed: 9331069
Roche J, Boldog F, Robinson M, Robinson L, Varella-Garcia M, Swanton M, et al. Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin. Oncogene 1996;12:1289–97.
pubmed: 8649831
van den Berg A, Buys CH. Involvement of multiple loci on chromosome 3 in renal cell cancer development. Genes Chromosomes Cancer. 1997;19:59–76.
pubmed: 9171996
doi: 10.1002/(SICI)1098-2264(199706)19:2<59::AID-GCC1>3.0.CO;2-Z
Wei MH, Latif F, Bader S, Kashuba V, Chen JY, Duh FM, et al. Construction of a 600-kilobase cosmid clone contig and generation of a transcriptional map surrounding the lung cancer tumor suppressor gene (TSG) locus on human chromosome 3p21.3: progress toward the isolation of a lung cancer TSG. Cancer Res. 1996;56:1487–92.
pubmed: 8603390
Wistuba II, Montellano FD, Milchgrub S, Virmani AK, Behrens C, Chen H, et al. Deletions of chromosome 3p are frequent and early events in the pathogenesis of uterine cervical carcinoma. Cancer Res. 1997;57:3154–8.
pubmed: 9242443
Rimessi P, Gualandi F, Morelli C, Trabanelli C, Wu Q, Possati L, et al. Transfer of human chromosome 3 to an ovarian carcinoma cell line identifies three regions on 3p involved in ovarian cancer. Oncogene 1994;9:3467–74.
pubmed: 7970706
Killary AM, Wolf ME, Giambernardi TA, Naylor SL. Definition of a tumor suppressor locus within human chromosome 3p21-p22. Proc Natl Acad Sci USA. 1992;89:10877–81.
pubmed: 1438292
pmcid: 50445
doi: 10.1073/pnas.89.22.10877
Cheng Y, Poulos NE, Lung ML, Hampton G, Ou B, Lerman MI, et al. Functional evidence for a nasopharyngeal carcinoma tumor suppressor gene that maps at chromosome 3p21.3. Proc Natl Acad Sci USA. 1998;95:3042–7.
pubmed: 9501212
pmcid: 19691
doi: 10.1073/pnas.95.6.3042
Daly MC, Xiang RH, Buchhagen D, Hensel CH, Garcia DK, Killary AM, et al. A homozygous deletion on chromosome 3 in a small cell lung cancer cell line correlates with a region of tumor suppressor activity. Oncogene 1993;8:1721–9.
pubmed: 8390035
Ji L, Nishizaki M, Gao B, Burbee D, Kondo M, Kamibayashi C, et al. Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. Cancer Res. 2002;62:2715–20.
pubmed: 11980673
pmcid: 3478680
Kondo M, Ji L, Kamibayashi C, Tomizawa Y, Randle D, Sekido Y, et al. Overexpression of candidate tumor suppressor gene FUS1 isolated from the 3p21.3 homozygous deletion region leads to G1 arrest and growth inhibition of lung cancer cells. Oncogene 2001;20:6258–62.
pubmed: 11593436
doi: 10.1038/sj.onc.1204832
Yazlovitskaya EM, Voziyan PA, Manavalan T, Yarbrough WG, Ivanova AV. Cellular oxidative stress response mediates radiosensitivity in Fus1-deficient mice. Cell Death Dis. 2015;6:e1652.
pubmed: 25695605
pmcid: 4669799
doi: 10.1038/cddis.2014.593
Yazlovitskaya EM, Uzhachenko R, Voziyan PA, Yarbrough WG, Ivanova AV. A novel radioprotective function for the mitochondrial tumor suppressor protein Fus1. Cell Death Dis. 2013;4:e687.
pubmed: 23788044
pmcid: 3702292
doi: 10.1038/cddis.2013.212
Tan WJT, Song L, Graham M, Schettino A, Navaratnam D, Yarbrough WG, et al. Novel role of the mitochondrial protein Fus1 in protection from premature hearing loss via regulation of oxidative stress and nutrient and energy sensing pathways in the inner ear. Antioxid Redox Signal. 2017;27:489–509.
pubmed: 28135838
pmcid: 5564041
doi: 10.1089/ars.2016.6851
Coronas-Samano G, Baker KL, Tan WJ, Ivanova AV, Verhagen JV. Fus1 KO mouse as a model of oxidative stress-mediated sporadic Alzheimer’s disease: circadian disruption and long-term spatial and olfactory memory impairments. Front Aging Neurosci. 2016;8:268.
pubmed: 27895577
pmcid: 5108791
doi: 10.3389/fnagi.2016.00268
Prudkin L, Behrens C, Liu DD, Zhou X, Ozburn NC, Bekele BN, et al. Loss and reduction of FUS1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer. Clin Cancer Res. 2008;14:41–7.
pubmed: 18172250
pmcid: 2833352
doi: 10.1158/1078-0432.CCR-07-1252
Uno F, Sasaki J, Nishizaki M, Carboni G, Xu K, Atkinson EN, et al. Myristoylation of the fus1 protein is required for tumor suppression in human lung cancer cells. Cancer Res. 2004;64:2969–76.
pubmed: 15126327
doi: 10.1158/0008-5472.CAN-03-3702
Lin J, Xu K, Gitanjali J, Roth JA, Ji L. Regulation of tumor suppressor gene FUS1 expression by the untranslated regions of mRNA in human lung cancer cells. Biochem Biophys Res Commun. 2011;410:235–41.
pubmed: 21645495
pmcid: 3129382
doi: 10.1016/j.bbrc.2011.05.122
Du L, Schageman JJ, Subauste MC, Saber B, Hammond SM, Prudkin L, et al. miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1. Mol Cancer Res. 2009;7:1234–43.
pubmed: 19671678
pmcid: 2741087
doi: 10.1158/1541-7786.MCR-08-0507
Xie HH, Huan WT, Han JQ, Ren WR, Yang LH. MicroRNA-663 facilitates the growth, migration and invasion of ovarian cancer cell by inhibiting TUSC2. Biol Res. 2019;52:18.
pubmed: 30944041
pmcid: 6448305
doi: 10.1186/s40659-019-0219-6
Yamamoto K, Ito S, Hanafusa H, Shimizu K, Ouchida M. Uncovering direct targets of MiR-19a involved in lung cancer progression. PLoS ONE. 2015;10:e0137887.
pubmed: 26367773
pmcid: 4569347
doi: 10.1371/journal.pone.0137887
Xing Y, Hou J, Guo T, Zheng S, Zhou C, Huang H, et al. microRNA-378 promotes mesenchymal stem cell survival and vascularization under hypoxic-ischemic conditions in vitro. Stem Cell Res Ther. 2014;5:130.
pubmed: 25418617
pmcid: 4446090
doi: 10.1186/scrt520
Orlandella FM, Di Maro G, Ugolini C, Basolo F, Salvatore G. TWIST1/miR-584/TUSC2 pathway induces resistance to apoptosis in thyroid cancer cells. Oncotarget 2016;7:70575–88.
pubmed: 27661106
pmcid: 5342575
doi: 10.18632/oncotarget.12129
Nama S, Muhuri M, Di Pascale F, Quah S, Aswad L, Fullwood M, et al. MicroRNA-138 is a prognostic biomarker for triple-negative breast cancer and promotes tumorigenesis via TUSC2 repression. Sci Rep. 2019;9:12718.
pubmed: 31481748
pmcid: 6722084
doi: 10.1038/s41598-019-49155-4
Rutnam ZJ, Du WW, Yang W, Yang X, Yang BB. The pseudogene TUSC2P promotes TUSC2 function by binding multiple microRNAs. Nat Commun. 2014;5:2914.
pubmed: 24394498
doi: 10.1038/ncomms3914
Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science 2013;339:1546–58.
pubmed: 23539594
pmcid: 3749880
doi: 10.1126/science.1235122
Hyun K, Jeon J, Park K, Kim J. Writing, erasing and reading histone lysine methylations. Exp Mol Med. 2017;49:e324.
pubmed: 28450737
pmcid: 6130214
doi: 10.1038/emm.2017.11
Rothbart SB, Strahl BD. Interpreting the language of histone and DNA modifications. Biochim Biophys Acta. 2014;1839:627–43.
pubmed: 24631868
pmcid: 4099259
doi: 10.1016/j.bbagrm.2014.03.001
Chow LS, Lo KW, Kwong J, To KF, Tsang KS, Lam CW. et al. RASSF1A is a target tumor suppressor from 3p21.3 in nasopharyngeal carcinoma. Int J Cancer. 2004;109:839–47.
pubmed: 15027117
doi: 10.1002/ijc.20079
da Costa Prando E, Cavalli LR, Rainho CA. Evidence of epigenetic regulation of the tumor suppressor gene cluster flanking RASSF1 in breast cancer cell lines. Epigenetics 2011;6:1413–24.
pubmed: 22139571
pmcid: 3256331
doi: 10.4161/epi.6.12.18271
Demokan S, Chuang AY, Chang X, Khan T, Smith IM, Pattani KM, et al. Identification of guanine nucleotide-binding protein gamma-7 as an epigenetically silenced gene in head and neck cancer by gene expression profiling. Int J Oncol. 2013;42:1427–36.
pubmed: 23403885
pmcid: 3981008
doi: 10.3892/ijo.2013.1808
Pastuszak-Lewandoska D, Kordiak J, Migdalska-Sek M, Czarnecka KH, Antczak A, Gorski P, et al. Quantitative analysis of mRNA expression levels and DNA methylation profiles of three neighboring genes: FUS1, NPRL2/G21 and RASSF1A in non-small cell lung cancer patients. Respir Res. 2015;16:76.
pubmed: 26112163
pmcid: 4484633
doi: 10.1186/s12931-015-0230-6
Ivanova AV, Ivanov SV, Prudkin L, Nonaka D, Liu Z, Tsao A, et al. Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects. Mol Cancer. 2009;8:91.
pubmed: 19852844
pmcid: 2776015
doi: 10.1186/1476-4598-8-91
Uzhachenko R, Issaeva N, Boyd K, Ivanov SV, Carbone DP, Ivanova AV. Tumour suppressor Fus1 provides a molecular link between inflammatory response and mitochondrial homeostasis. J Pathol. 2012;227:456–69.
pubmed: 22513871
doi: 10.1002/path.4039
Kim I, Kim JH, Kim K, Seong S, Kim N. Tusc2/Fus1 regulates osteoclast differentiation through NF-kappaB and NFATc1. BMB Rep. 2017;50:454–9.
pubmed: 28391779
pmcid: 5625692
doi: 10.5483/BMBRep.2017.50.9.026
Piskacek S, Gregor M, Nemethova M, Grabner M, Kovarik P, Piskacek M. Nine-amino-acid transactivation domain: establishment and prediction utilities. Genomics 2007;89:756–68.
pubmed: 17467953
doi: 10.1016/j.ygeno.2007.02.003
Udenwobele DI, Su RC, Good SV, Ball TB, Varma Shrivastav S, Shrivastav A. Myristoylation: an important protein modification in the immune response. Front Immunol. 2017;8:751.
pubmed: 28713376
pmcid: 5492501
doi: 10.3389/fimmu.2017.00751
Ames JB, Ishima R, Tanaka T, Gordon JI, Stryer L, Ikura M. Molecular mechanics of calcium-myristoyl switches. Nature 1997;389:198–202.
pubmed: 9296500
doi: 10.1038/38310
Zozulya S, Stryer L. Calcium-myristoyl protein switch. Proc Natl Acad Sci USA. 1992;89:11569–73.
pubmed: 1454850
pmcid: 50594
doi: 10.1073/pnas.89.23.11569
Larsen SC, Sylvestersen KB, Mund A, Lyon D, Mullari M, Madsen MV, et al. Proteome-wide analysis of arginine monomethylation reveals widespread occurrence in human cells. Sci Signal. 2016;9:rs9.
pubmed: 27577262
doi: 10.1126/scisignal.aaf7329
Bouhaddou M, Memon D, Meyer B, White KM, Rezelj VV, Correa Marrero M, et al. The global phosphorylation landscape of SARS-CoV-2 infection. Cell 2020;182:685–712.e19.
pubmed: 32645325
pmcid: 7321036
doi: 10.1016/j.cell.2020.06.034
Mertins P, Qiao JW, Patel J, Udeshi ND, Clauser KR, Mani DR, et al. Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods. 2013;10:634–7.
pubmed: 23749302
pmcid: 3943163
doi: 10.1038/nmeth.2518
Pathak T, Trebak M. Mitochondrial Ca(2+) signaling. Pharm Ther. 2018;192:112–23.
doi: 10.1016/j.pharmthera.2018.07.001
Nemani N, Shanmughapriya S, Madesh M. Molecular regulation of MCU: Implications in physiology and disease. Cell Calcium. 2018;74:86–93.
pubmed: 29980025
pmcid: 6119482
doi: 10.1016/j.ceca.2018.06.006
Boyman L, Greiser M, Lederer WJ. Calcium influx through the mitochondrial calcium uniporter holocomplex, MCUcx. J Mol Cell Cardiol. 2021;151:145–54.
pubmed: 33147447
doi: 10.1016/j.yjmcc.2020.10.015
Padanyi R, Paszty K, Hegedus L, Varga K, Papp B, Penniston JT, et al. Multifaceted plasma membrane Ca(2+) pumps: From structure to intracellular Ca(2+) handling and cancer. Biochim Biophys Acta. 2016;1863:1351–63.
pubmed: 26707182
doi: 10.1016/j.bbamcr.2015.12.011
Yoo J, Wu M, Yin Y, Herzik MA Jr., Lander GC, Lee SY. Cryo-EM structure of a mitochondrial calcium uniporter. Science 2018;361:506–11.
pubmed: 29954988
pmcid: 6155975
doi: 10.1126/science.aar4056
Csordas G, Golenar T, Seifert EL, Kamer KJ, Sancak Y, Perocchi F, et al. MICU1 controls both the threshold and cooperative activation of the mitochondrial Ca(2)(+) uniporter. Cell Metab. 2013;17:976–87.
pubmed: 23747253
pmcid: 3722067
doi: 10.1016/j.cmet.2013.04.020
Mallilankaraman K, Doonan P, Cardenas C, Chandramoorthy HC, Muller M, Miller R, et al. MICU1 is an essential gatekeeper for MCU-mediated mitochondrial Ca(2
pubmed: 23101630
pmcid: 3486697
doi: 10.1016/j.cell.2012.10.011
de la Fuente S, Matesanz-Isabel J, Fonteriz RI, Montero M, Alvarez J. Dynamics of mitochondrial Ca2
pubmed: 24313810
doi: 10.1042/BJ20131025
Patron M, Checchetto V, Raffaello A, Teardo E, Vecellio Reane D, Mantoan M, et al. MICU1 and MICU2 finely tune the mitochondrial Ca2
pubmed: 24560927
pmcid: 3988891
doi: 10.1016/j.molcel.2014.01.013
Giorgi C, Bonora M, Missiroli S, Poletti F, Ramirez FG, Morciano G, et al. Intravital imaging reveals p53-dependent cancer cell death induced by phototherapy via calcium signaling. Oncotarget 2015;6:1435–45.
pubmed: 25544762
doi: 10.18632/oncotarget.2935
Bononi A, Bonora M, Marchi S, Missiroli S, Poletti F, Giorgi C, et al. Identification of PTEN at the ER and MAMs and its regulation of Ca(2+) signaling and apoptosis in a protein phosphatase-dependent manner. Cell Death Differ. 2013;20:1631–43.
pubmed: 23811847
pmcid: 3824603
doi: 10.1038/cdd.2013.77
Marchi S, Lupini L, Patergnani S, Rimessi A, Missiroli S, Bonora M, et al. Downregulation of the mitochondrial calcium uniporter by cancer-related miR-25. Curr Biol. 2013;23:58–63.
pubmed: 23246404
pmcid: 3540261
doi: 10.1016/j.cub.2012.11.026
Sekler I. Standing of giants shoulders the story of the mitochondrial Na(+)Ca(2
pubmed: 25998733
doi: 10.1016/j.bbrc.2015.02.170
Delierneux C, Kouba S, Shanmughapriya S, Potier-Cartereau M, Trebak M, Hempel N. Mitochondrial calcium regulation of redox signaling in cancer. Cells. 2020;2:432.
Pathak T, Gueguinou M, Walter V, Delierneux C, Johnson MT, Zhang X, et al. Dichotomous role of the human mitochondrial Na(+)/Ca2(+)/Li(+) exchanger NCLX in colorectal cancer growth and metastasis. Elife. 2020;9:e59686.
Koval OM, Nguyen EK, Santhana V, Fidler TP, Sebag SC, Rasmussen TP, et al. Loss of MCU prevents mitochondrial fusion in G1-S phase and blocks cell cycle progression and proliferation. Sci Signal. 2019;579:eaav1439.
Dikalov SI, Li W, Doughan AK, Blanco RR, Zafari AM. Mitochondrial reactive oxygen species and calcium uptake regulate activation of phagocytic NADPH oxidase. Am J Physiol Regul Integr Comp Physiol. 2012;302:R1134–42.
pubmed: 22442197
pmcid: 3362147
doi: 10.1152/ajpregu.00842.2010
Hoffman NE, Chandramoorthy HC, Shamugapriya S, Zhang X, Rajan S, Mallilankaraman K, et al. MICU1 motifs define mitochondrial calcium uniporter binding and activity. Cell Rep. 2013;5:1576–88.
pubmed: 24332854
pmcid: 3919628
doi: 10.1016/j.celrep.2013.11.026
Paillard M, Csordas G, Huang KT, Varnai P, Joseph SK, Hajnoczky G. MICU1 interacts with the D-ring of the MCU pore to control its Ca(2+) flux and sensitivity to Ru360. Mol Cell. 2018;72:778–85.e3.
pubmed: 30454562
pmcid: 6251499
doi: 10.1016/j.molcel.2018.09.008
Lin J, Sun T, Ji L, Deng W, Roth J, Minna J, et al. Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1. Oncogene 2007;26:6989–96.
pubmed: 17486070
pmcid: 3457636
doi: 10.1038/sj.onc.1210500
Lin J, Arlinghaus R. Activated c-Abl tyrosine kinase in malignant solid tumors. Oncogene 2008;27:4385–91.
pubmed: 18391983
doi: 10.1038/onc.2008.86
Hantschel O, Nagar B, Guettler S, Kretzschmar J, Dorey K, Kuriyan J, et al. A myristoyl/phosphotyrosine switch regulates c-Abl. Cell 2003;112:845–57.
pubmed: 12654250
doi: 10.1016/S0092-8674(03)00191-0
Shental-Bechor D, Smith MT, Mackenzie D, Broom A, Marcovitz A, Ghashut F, et al. Nonnative interactions regulate folding and switching of myristoylated protein. Proc Natl Acad Sci USA. 2012;109:17839–44.
pubmed: 22847411
pmcid: 3497764
doi: 10.1073/pnas.1201803109
Skora L, Mestan J, Fabbro D, Jahnke W, Grzesiek S. NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors. Proc Natl Acad Sci USA. 2013;110:E4437–45.
pubmed: 24191057
pmcid: 3839726
doi: 10.1073/pnas.1314712110
Plattner R, Pendergast AM. Activation and signaling of the Abl tyrosine kinase: bidirectional link with phosphoinositide signaling. Cell Cycle. 2003;2:273–4.
pubmed: 12851468
doi: 10.4161/cc.2.4.409
Liberatore RA, Goff SP. c-Abl-deficient mice exhibit reduced numbers of peritoneal B-1 cells and defects in BCR-induced B cell activation. Int Immunol. 2009;21:403–14.
pubmed: 19228876
pmcid: 2660863
doi: 10.1093/intimm/dxp006
Antony AN, Paillard M, Moffat C, Juskeviciute E, Correnti J, Bolon B, et al. MICU1 regulation of mitochondrial Ca(2+) uptake dictates survival and tissue regeneration. Nat Commun. 2016;7:10955.
pubmed: 26956930
pmcid: 4786880
doi: 10.1038/ncomms10955
Feng X, McDonald JM. Disorders of bone remodeling. Annu Rev Pathol. 2011;6:121–45.
pubmed: 20936937
pmcid: 3571087
doi: 10.1146/annurev-pathol-011110-130203
Deschenes-Simard X, Kottakis F, Meloche S, Ferbeyre G. ERKs in cancer: friends or foes? Cancer Res. 2014;74:412–9.
pubmed: 24408923
doi: 10.1158/0008-5472.CAN-13-2381
Guy GR, Jackson RA, Yusoff P, Chow SY. Sprouty proteins: modified modulators, matchmakers or missing links? J Endocrinol. 2009;203:191–202.
pubmed: 19423641
doi: 10.1677/JOE-09-0110
Macia A, Vaquero M, Gou-Fabregas M, Castelblanco E, Valdivielso JM, Anerillas C, et al. Sprouty1 induces a senescence-associated secretory phenotype by regulating NFkappaB activity: implications for tumorigenesis. Cell Death Differ. 2014;21:333–43.
pubmed: 24270409
doi: 10.1038/cdd.2013.161
Montico B, Colizzi F, Giurato G, Rizzo A, Salvati A, Baboci L, et al. Loss of Spry1 reduces growth of BRAF(V600)-mutant cutaneous melanoma and improves response to targeted therapy. Cell Death Dis. 2020;11:392.
pubmed: 32444628
pmcid: 7244546
doi: 10.1038/s41419-020-2585-y
Alimonti A, Nardella C, Chen Z, Clohessy JG, Carracedo A, Trotman LC, et al. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest. 2010;120:681–93.
pubmed: 20197621
pmcid: 2827955
doi: 10.1172/JCI40535
Jung SH, Hwang HJ, Kang D, Park HA, Lee HC, Jeong D, et al. mTOR kinase leads to PTEN-loss-induced cellular senescence by phosphorylating p53. Oncogene 2019;38:1639–50.
pubmed: 30337688
doi: 10.1038/s41388-018-0521-8
Deng WG, Kawashima H, Wu G, Jayachandran G, Xu K, Minna JD, et al. Synergistic tumor suppression by coexpression of FUS1 and p53 is associated with down-regulation of murine double minute-2 and activation of the apoptotic protease-activating factor 1-dependent apoptotic pathway in human non-small cell lung cancer cells. Cancer Res. 2007;67:709–17.
pubmed: 17234782
doi: 10.1158/0008-5472.CAN-06-3463
Ito I, Ji L, Tanaka F, Saito Y, Gopalan B, Branch CD, et al. Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo. Cancer Gene Ther. 2004;11:733–9.
pubmed: 15486560
doi: 10.1038/sj.cgt.7700756
Mariniello RM, Orlandella FM, Stefano AE, Iervolino PLC, Smaldone G, Luciano N, et al. The TUSC2 tumour suppressor inhibits the malignant phenotype of human thyroid cancer cells via SMAC/DIABLO protein. Int J Mol Sci. 2020;3:702.
Jayachandran G, Roth JA, Ji L. Analysis of protein-protein interaction using proteinchip array-based SELDI-TOF mass spectrometry. Methods Mol Biol. 2012;818:217–26.
pubmed: 22083826
pmcid: 3369541
doi: 10.1007/978-1-61779-418-6_15
Birch J & Passos JF. Targeting the SASP to combat ageing: mitochondria as possible intracellular allies? Bioessays. 2017;5:1600235.
Chapman J, Fielder E, Passos JF. Mitochondrial dysfunction and cell senescence: deciphering a complex relationship. FEBS Lett. 2019;593:1566–79.
pubmed: 31211858
doi: 10.1002/1873-3468.13498
Engin AB, Engin A. The connection between cell fate and telomere. Adv Exp Med Biol. 2021;1275:71–100.
pubmed: 33539012
doi: 10.1007/978-3-030-49844-3_3
Mijit M, Caracciolo V, Melillo A, Amicarelli F, Giordano A. Role of p53 in the regulation of cellular senescence. Biomolecules. 2020;10:420.
pmcid: 7175209
doi: 10.3390/biom10030420
Schosserer M, Grillari J, Breitenbach M. The dual role of cellular senescence in developing tumors and their response to cancer therapy. Front Oncol. 2017;7:278.
pubmed: 29218300
pmcid: 5703792
doi: 10.3389/fonc.2017.00278
Franco J, Balaji U, Freinkman E, Witkiewicz AK, Knudsen ES. Metabolic reprogramming of pancreatic cancer mediated by CDK4/6 inhibition elicits unique vulnerabilities. Cell Rep. 2020;32:107793.
pubmed: 32640213
pmcid: 9540600
doi: 10.1016/j.celrep.2020.107793
Basisty N, Kale A, Jeon OH, Kuehnemann C, Payne T, Rao C, et al. A proteomic atlas of senescence-associated secretomes for aging biomarker development. PLoS Biol. 2020;18:e3000599.
pubmed: 31945054
pmcid: 6964821
doi: 10.1371/journal.pbio.3000599
Gonzalez-Meljem JM, Apps JR, Fraser HC, Martinez-Barbera JP. Paracrine roles of cellular senescence in promoting tumourigenesis. Br J Cancer. 2018;118:1283–8.
pubmed: 29670296
pmcid: 5959857
doi: 10.1038/s41416-018-0066-1
Saleh T, Tyutynuk-Massey L, Cudjoe EK Jr, Idowu MO, Landry JW, Gewirtz DA. Non-cell autonomous effects of the senescence-associated secretory phenotype in cancer therapy. Front Oncol. 2018;8:164.
pubmed: 29868482
pmcid: 5968105
doi: 10.3389/fonc.2018.00164
Xu M, Bradley EW, Weivoda MM, Hwang SM, Pirtskhalava T, Decklever T, et al. Transplanted senescent cells induce an osteoarthritis-like condition in mice. J Gerontol A Biol Sci Med Sci. 2017;72:780–5.
pubmed: 27516624
Roberts-Thomson SJ, Chalmers SB, Monteith GR. The calcium-signaling toolkit in cancer: remodeling and targeting. Cold Spring Harb Perspect Biol. 2019;8:a035204.
Martin N, Bernard D. Calcium signaling and cellular senescence. Cell Calcium. 2018;70:16–23.
pubmed: 28410770
doi: 10.1016/j.ceca.2017.04.001
Xin J, Zhang XK, Xin DY, Li XF, Sun DK, Ma YY, et al. FUS1 acts as a tumor-suppressor gene by upregulating miR-197 in human glioblastoma. Oncol Rep. 2015;34:868–76.
pubmed: 26081814
doi: 10.3892/or.2015.4069
Kale A, Sharma A, Stolzing A, Desprez PY, Campisi J. Role of immune cells in the removal of deleterious senescent cells. Immun Ageing. 2020;17:16.
pubmed: 32518575
pmcid: 7271494
doi: 10.1186/s12979-020-00187-9
Mouton-Liger F, Jacoupy M, Corvol JC, Corti O. PINK1/Parkin-dependent mitochondrial surveillance: from pleiotropy to Parkinson’s disease. Front Mol Neurosci. 2017;10:120.
pubmed: 28507507
pmcid: 5410576
doi: 10.3389/fnmol.2017.00120
Korolchuk VI, Miwa S, Carroll B, von Zglinicki T. Mitochondria in cell senescence: is mitophagy the weakest link? EBioMedicine 2017;21:7–13.
pubmed: 28330601
pmcid: 5514379
doi: 10.1016/j.ebiom.2017.03.020
Nakamura Y, Iwata H, Kuwayama T, Shirasuna KS100A8. which increases with age, induces cellular senescence-like changes in bovine oviduct epithelial cells. Am J Reprod Immunol. 2019;82:e13163.
pubmed: 31237976
doi: 10.1111/aji.13163
Levi N, Papismadov N, Solomonov I, Sagi I, Krizhanovsky V. The ECM path of senescence in aging: components and modifiers. FEBS J. 2020;287:2636–46.
pubmed: 32145148
doi: 10.1111/febs.15282
Swindell WR, Johnston A, Xing X, Little A, Robichaud P, Voorhees JJ, et al. Robust shifts in S100a9 expression with aging: a novel mechanism for chronic inflammation. Sci Rep. 2013;3:1215.
pubmed: 23386971
pmcid: 3564041
doi: 10.1038/srep01215
Spranger S, Gajewski TF. Impact of oncogenic pathways on evasion of antitumour immune responses. Nat Rev Cancer. 2018;18:139–47.
pubmed: 29326431
pmcid: 6685071
doi: 10.1038/nrc.2017.117
Chen R, Manochakian R, James L, Azzouqa AG, Shi H, Zhang Y, et al. Emerging therapeutic agents for advanced non-small cell lung cancer. J Hematol Oncol. 2020;13:58.
pubmed: 32448366
pmcid: 7245927
doi: 10.1186/s13045-020-00881-7
Meng J, Majidi M, Fang B, Ji L, Bekele BN, Minna JD, et al. The tumor suppressor gene TUSC2 (FUS1) sensitizes NSCLC to the AKT inhibitor MK2206 in LKB1-dependent manner. PLoS ONE. 2013;8:e77067.
pubmed: 24146957
pmcid: 3798310
doi: 10.1371/journal.pone.0077067
Xiaobo C, Majidi M, Feng M, Shao R, Wang J, Zhao Y, et al. TUSC2(FUS1)-erlotinib induced vulnerabilities in epidermal growth factor receptor(EGFR) wildtype non-small cell lung cancer (NSCLC) targeted by the repurposed drug auranofin. Sci Rep. 2016;6:35741.
pubmed: 27845352
pmcid: 5109231
doi: 10.1038/srep35741
Cao X, Zhao Y, Wang J, Dai B, Gentile E, Lin J, et al. TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC). Oncotarget 2017;8:107621–9.
pubmed: 29296193
pmcid: 5746095
doi: 10.18632/oncotarget.22581
Lorenz R, Bernhart SH, Honer Zu Siederdissen C, Tafer H, Flamm C, Stadler PF, et al. ViennaRNA Package 2.0. Algorithms Mol Biol. 2011;6:26.
pubmed: 22115189
pmcid: 3319429
doi: 10.1186/1748-7188-6-26
Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 2018;46:W296–W303.
pubmed: 29788355
pmcid: 6030848
doi: 10.1093/nar/gky427
Kozakov D, Hall DR, Xia B, Porter KA, Padhorny D, Yueh C, et al. The ClusPro web server for protein-protein docking. Nat Protoc. 2017;12:255–78.
pubmed: 28079879
pmcid: 5540229
doi: 10.1038/nprot.2016.169